CN109071646A - TGFβ1-结合免疫球蛋白及其用途 - Google Patents

TGFβ1-结合免疫球蛋白及其用途 Download PDF

Info

Publication number
CN109071646A
CN109071646A CN201780023887.8A CN201780023887A CN109071646A CN 109071646 A CN109071646 A CN 109071646A CN 201780023887 A CN201780023887 A CN 201780023887A CN 109071646 A CN109071646 A CN 109071646A
Authority
CN
China
Prior art keywords
antibody
tgf
antigen
binding portion
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780023887.8A
Other languages
English (en)
Chinese (zh)
Inventor
T·舒尔普夫
G·J·卡文
A·达塔
K·朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stone Supply Co
Original Assignee
Stone Supply Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58503696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109071646(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stone Supply Co filed Critical Stone Supply Co
Publication of CN109071646A publication Critical patent/CN109071646A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780023887.8A 2016-03-11 2017-03-10 TGFβ1-结合免疫球蛋白及其用途 Pending CN109071646A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662307353P 2016-03-11 2016-03-11
US62/307,353 2016-03-11
US201762443615P 2017-01-06 2017-01-06
US62/443,615 2017-01-06
US201762452866P 2017-01-31 2017-01-31
US62/452,866 2017-01-31
PCT/US2017/021972 WO2017156500A1 (en) 2016-03-11 2017-03-10 Tgfb1-binding immunoglobulins and use thereof

Publications (1)

Publication Number Publication Date
CN109071646A true CN109071646A (zh) 2018-12-21

Family

ID=58503696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780023887.8A Pending CN109071646A (zh) 2016-03-11 2017-03-10 TGFβ1-结合免疫球蛋白及其用途

Country Status (19)

Country Link
US (2) US11643459B2 (https=)
EP (2) EP3365368B1 (https=)
JP (4) JP2019509737A (https=)
KR (3) KR20180122397A (https=)
CN (1) CN109071646A (https=)
AU (2) AU2017230103A1 (https=)
BR (1) BR112018068340A2 (https=)
CA (1) CA3055555A1 (https=)
DK (1) DK3365368T3 (https=)
EA (1) EA201891909A1 (https=)
ES (1) ES2951648T3 (https=)
FI (1) FI3365368T3 (https=)
HU (1) HUE062976T2 (https=)
IL (2) IL307835A (https=)
MX (2) MX2018010948A (https=)
PL (1) PL3365368T3 (https=)
PT (1) PT3365368T (https=)
SG (1) SG11201807176XA (https=)
WO (1) WO2017156500A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113677711A (zh) * 2019-01-30 2021-11-19 供石公司 TGFβ的LTBP复合特异性抑制剂及其用途
WO2022152285A1 (zh) * 2021-01-18 2022-07-21 上海济煜医药科技有限公司 Garp蛋白抗体及其应用
WO2022206753A1 (zh) * 2021-03-29 2022-10-06 山东先声生物制药有限公司 GARP/TGFβ1抗体及其应用
CN115190812A (zh) * 2020-01-11 2022-10-14 供石公司 TGFβ抑制剂及其用途
CN115335393A (zh) * 2020-03-24 2022-11-11 博奥泰克尼公司 使用TGFβ敲除细胞系及由其产生的组合物的方法
WO2024149237A1 (zh) * 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
TWI923549B (zh) 2019-01-30 2026-05-01 美商供石公司 TGFβ之LTBP複合物專一性抑制劑及其用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
US20190292254A1 (en) * 2016-07-14 2019-09-26 Scholar Rock, Inc. TGFBeta Antibodies, Methods and Uses
PE20191661A1 (es) 2017-01-06 2019-11-11 Scholar Rock Inc Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
EP3600322A1 (en) * 2017-03-28 2020-02-05 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of muscular dystrophy
PT3621694T (pt) 2017-05-09 2023-10-09 Scholar Rock Inc Inibidores de lrrc33 e sua utilização
US12358992B2 (en) * 2017-07-28 2025-07-15 Scholar Rock, Inc. LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US20210115122A1 (en) * 2018-02-23 2021-04-22 Chugai Seiyaku Kabushiki Kaisha Cross-species anti-latent tgf-beta 1 antibodies and methods of use
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
MX2021000347A (es) 2018-07-11 2021-04-19 Scholar Rock Inc Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
PL3677278T3 (pl) 2018-07-11 2022-02-28 Scholar Rock, Inc. Selektywne względem izoformy inhibitory tgfbeta1 i ich zastosowanie
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
WO2020095113A1 (en) * 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
CA3135988C (en) * 2019-06-10 2024-11-19 Shandong Boan Biotechnology Co., Ltd. Bifunctional fusion protein against PD-L1 and TGFS and its use
BR112022003412A2 (pt) 2019-08-28 2022-05-24 Chugai Pharmaceutical Co Ltd Anticorpos anti-tgf-beta 1 latente de espécies cruzadas e métodos de uso
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
JP7280400B2 (ja) * 2021-02-26 2023-05-23 中外製薬株式会社 種交差性抗潜在型ＴＧＦ－β１抗体の使用
WO2022180764A1 (en) 2021-02-26 2022-09-01 Chugai Seiyaku Kabushiki Kaisha Uses of cross-species anti-latent tgf-beta 1 antibodies
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
CA3244596A1 (en) 2022-03-29 2023-10-05 Allogene Therapeutics, Inc. Chimeric switch receivers for converting immunoactive signals into stimulation signals
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
GB202219154D0 (en) * 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
PE20252310A1 (es) 2023-02-10 2025-09-22 Chugai Pharmaceutical Co Ltd Anticuerpos anti-tgf-beta 1 latente y metodos de uso
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
CN120131938B (zh) * 2025-03-19 2025-12-23 广州奥奇生物技术有限公司 一种益生菌制剂的制备方法及其在改善睡眠中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023870A1 (ja) * 2003-09-04 2005-03-17 Riken ＴＧＦ－β活性化制御領域の切断面を認識する抗体
CN101163502A (zh) * 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
CN101163719A (zh) * 2005-04-22 2008-04-16 伊莱利利公司 TGFβ1特异性抗体
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
WO2012167143A1 (en) * 2011-06-03 2012-12-06 Xoma Technology Ltd. Antibodies specific for tgf-beta
WO2013134365A1 (en) * 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
WO2014182676A2 (en) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
CA2250166A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
GB0230202D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Ligand
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
PT2125894T (pt) 2007-03-22 2019-02-27 Biogen Ma Inc Proteínas de ligação incluindo anticorpos, derivados de anticorpos e fragmentos de anticorpos que se ligam especificamente ao cd154 e as suas utilizações
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
JP5918275B2 (ja) 2011-02-08 2016-05-18 アッヴィ・インコーポレイテッド 変形性関節症及び疼痛の治療
SG10201603962TA (en) 2011-05-25 2016-07-28 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
BR112013031485B1 (pt) 2011-06-10 2022-06-14 Medimmune, Llc Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
CN109111523B (zh) 2011-10-14 2022-06-07 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
RU2014114015A (ru) 2011-11-08 2015-12-20 Пфайзер Инк. Способы лечения воспалительных расстройств с использованием антител против m-csf
AU2012339722B2 (en) 2011-11-14 2017-09-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
US20150284455A1 (en) 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2015015003A1 (en) * 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
US20170073406A1 (en) 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CN114306596A (zh) 2014-06-26 2022-04-12 海德堡免疫疗法有限公司 抗hsv抗体的局部应用
BR112017009931A2 (pt) 2014-11-18 2018-02-14 Pasteur Institut anticorpos policlonais, agente de diagnóstico, método de detecção de sorogrupo x de neisseria meningitidis in vitro, método in vitro de diagnóstico de infecção no sorogrupo x de neisseria meningitidis, kit e teste de diagnóstico, uso do kit de diagnóstico e método de produção de anticorpos policlonais
EP3244926B8 (en) 2015-01-14 2024-08-21 The Brigham and Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
US20190292254A1 (en) 2016-07-14 2019-09-26 Scholar Rock, Inc. TGFBeta Antibodies, Methods and Uses
PE20191661A1 (es) 2017-01-06 2019-11-11 Scholar Rock Inc Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023870A1 (ja) * 2003-09-04 2005-03-17 Riken ＴＧＦ－β活性化制御領域の切断面を認識する抗体
CN101163502A (zh) * 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
CN101163719A (zh) * 2005-04-22 2008-04-16 伊莱利利公司 TGFβ1特异性抗体
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
WO2012167143A1 (en) * 2011-06-03 2012-12-06 Xoma Technology Ltd. Antibodies specific for tgf-beta
WO2013134365A1 (en) * 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
WO2014182676A2 (en) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRAUNINGER,A. ET AL.: "immunoglobulin kappa chain variable region, partial [Homo sapiens]，GenBank: CAC10871.1", 《GENBANK》 *
JULIA CUENDE ET AL.: "Monoclonal antibodies against GARP/TGF-b1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo", 《SCI.TRANSL. MED.》 *
郭永红等: "重组转化生长因子β1疫苗诱导产生抗体的活性检测及抗纤维化作用", 《中华肝脏病杂志》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113677711A (zh) * 2019-01-30 2021-11-19 供石公司 TGFβ的LTBP复合特异性抑制剂及其用途
US12173059B2 (en) 2019-01-30 2024-12-24 Scholar Rock, Inc. LTBP complex-specific inhibitors of TGFβ and uses thereof
TWI923549B (zh) 2019-01-30 2026-05-01 美商供石公司 TGFβ之LTBP複合物專一性抑制劑及其用途
CN115190812A (zh) * 2020-01-11 2022-10-14 供石公司 TGFβ抑制剂及其用途
CN115335393A (zh) * 2020-03-24 2022-11-11 博奥泰克尼公司 使用TGFβ敲除细胞系及由其产生的组合物的方法
WO2022152285A1 (zh) * 2021-01-18 2022-07-21 上海济煜医药科技有限公司 Garp蛋白抗体及其应用
WO2022206753A1 (zh) * 2021-03-29 2022-10-06 山东先声生物制药有限公司 GARP/TGFβ1抗体及其应用
WO2024149237A1 (zh) * 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途

Also Published As

Publication number Publication date
PT3365368T (pt) 2023-08-17
US11643459B2 (en) 2023-05-09
HUE062976T2 (hu) 2023-12-28
JP7794630B2 (ja) 2026-01-06
JP2022031403A (ja) 2022-02-18
AU2024202692A1 (en) 2024-05-30
EA201891909A1 (ru) 2019-02-28
PL3365368T3 (pl) 2023-08-21
KR20180122397A (ko) 2018-11-12
JP2022028680A (ja) 2022-02-16
EP4169942A1 (en) 2023-04-26
JP2019509737A (ja) 2019-04-11
KR20250011248A (ko) 2025-01-21
CA3055555A1 (en) 2017-09-14
MX2018010948A (es) 2019-06-20
JP2023108057A (ja) 2023-08-03
SG11201807176XA (en) 2018-09-27
AU2017230103A1 (en) 2018-09-06
EP3365368B1 (en) 2023-05-17
WO2017156500A8 (en) 2018-01-25
BR112018068340A2 (pt) 2019-01-15
WO2017156500A9 (en) 2018-02-22
KR20230088508A (ko) 2023-06-19
US20230348583A1 (en) 2023-11-02
EP3365368A1 (en) 2018-08-29
DK3365368T3 (da) 2023-06-26
IL261442A (en) 2018-10-31
IL307835A (en) 2023-12-01
US20190071493A1 (en) 2019-03-07
WO2017156500A1 (en) 2017-09-14
FI3365368T3 (fi) 2023-06-13
MX2024005811A (es) 2024-05-28
ES2951648T3 (es) 2023-10-24

Similar Documents

Publication Publication Date Title
CN109071646A (zh) TGFβ1-结合免疫球蛋白及其用途
US20240016928A1 (en) Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
JP7829605B2 (ja) コネキシン４３抗体およびその使用
KR20210058811A (ko) 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
CN109071645A (zh) 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
TW201113036A (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
HK40089584A (en) Tgfbeta1-binding immunoglobulins and use thereof
HK1260186A1 (en) Tgfbeta1-binding immunoglobulins and use thereof
HK1260186B (en) Tgfbeta1-binding immunoglobulins and use thereof
HK40100613A (zh) 连接蛋白43抗体及其用途
EA048751B1 (ru) TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ
BR122024003721A2 (pt) IMUNOGLOBULINAS DE LIGAÇÃO AO TGFbeta1 E USOS DESTAS
EA045239B1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination